Immuneering Corp (IMRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Immuneering Corp (IMRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Grant C. Bo
- Person
- Grant C. Bogle, MBA
- Title
- member of the Company's Board as a Class III Director
- Action
- appointed
- Effective
- November 9, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The filing is a routine corporate governance disclosure with no material financial impact.
Market read
Low relevance; typical governance filing with limited trading implications.
What to watch
Potential hidden strategic shifts if the director has industry connections.
Background
Immuneering Corp filed a Form 8‑K on Nov 9, 2026 announcing a board appointment.
Ticker impact
SEC 8‑K filing reports appointment of Grant C. Bogle as a Class III director and related indemnification agreements.
likely neutral as market prices in the appointment with no material change to strategy.
Director appointments are routine corporate governance events that rarely move share price.
Market effects
Minimal; governance change does not affect the broader biotech sector.
None; company is US‑listed and the filing is company‑specific.
None
Counterpoint
If the new director brings unique expertise, there could be a modest upside.
Key entities
- companyImmuneering Corp
Biotech firm listed on NASDAQ under IMRX.
- personGrant C. Bogle
Appointed Class III director.


